BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts

BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its ...

BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth

BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential ...
Nasdaq

BridgeBio Pharma Reports Strong Early Demand for Attruby and Updates on Phase 3 Clinical Trials

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...
Seeking Alpha

BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore

BridgeBio remains a compelling Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics following Pfizer’s patent settlements. Attruby’s peak annual sales are conservatively ...
STAT

Sales of BridgeBio’s new heart drug blow past expectations

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
Seeking Alpha

BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts

BBIO’s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer’s Tafamidis and Alnylam’s Amvuttra. Its US uptake keeps ...
STAT

BridgeBio wins FDA approval for heart disease drug

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
FiercePharma

BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’

To help BridgeBio ramp up for the launch of three new medicines, plus approved ATTR-CM med Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech ...
MedCity News

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...
Insider Monkey

UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...
Wall Street Journal

A Short Lesson in Drug Competition

Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new treatments launched by biotech startups. Late last week the FDA approved ...